Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer: Is K-RAS mutational testing ready for prime time? | springermedizin.at

Springer Medizin Österreich

nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2011 | Controversy

Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer: Is K-RAS mutational testing ready for prime time?

verfasst von: T. Bauernhofer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Anzeige

Vorheriger Artikel Surgical topics of interest at the 14th World Conference on Lung Cancer

Nächster Artikel The role of radiochemotherapy in the multimodal treatment of pancreatic ductal adenocarcinoma: Standard procedure or individual decision?

Titel: Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer: Is K-RAS mutational testing ready for prime time?
verfasst von: T. Bauernhofer
Publikationsdatum: 01.12.2011
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2011
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-011-0302-3

Weitere Artikel der Ausgabe 4/2011

Cancer in the elderly and gender aspects – situation in Tyrol

Short review

Preclinical research in oncology: Gender aspects

Short review

Gender aspects in tumours of the nervous system

Short review

The role of oncology in the context to gender medicine

Editorial

Treatment of invasive aspergillosis in cancer patients

Short review

A histology-based algorithm in the molecular diagnosis of mutations of the epidermal growth factor receptor (EGFR)–in non-small-cell lung cancer (NSCLC)*

Consensus report